Perspective Therapeutics filings document a clinical-stage radiopharmaceutical oncology business built around Lead-212 targeted therapy, imaging diagnostics, and regional manufacturing capabilities. Form 8-K reports include clinical-program exhibits, corporate presentations, preliminary financial information, and annual results for its VMT-α-NET, VMT01, and PSV359 programs.
The company’s SEC record also covers capital-structure matters, including common stock and pre-funded warrant offerings under a shelf registration statement, as well as material agreements, proxy disclosures on board matters, executive compensation, equity awards, shareholder voting items, governance, and other public-company reporting obligations.
Perspective Therapeutics, Inc. amendment to a Schedule 13G shows Morgan Stanley reporting shared voting power of 2,930,734 shares and shared dispositive power of 2,959,296 shares in the issuer's common stock. The filing states the position equals 2.6% of the class.
The filing includes the statement, verbatim, that "As of the date hereof, Morgan Stanley has ceased to be the beneficial owner of more than five percent of the class of securities." The form lists CUSIP 46489V302 and is signed by an authorized Morgan Stanley signatory on 05/12/2026.
Perspective Therapeutics reported a larger net loss as it ramped up development of its radiopharmaceutical pipeline in the quarter ended March 31, 2026. Net loss was $26.2 million, or $0.25 per share, compared with $18.2 million a year earlier, driven mainly by higher research and development spending.
Research and development expense rose to $21.4 million from $14.3 million as the company advanced its VMT-α-NET, VMT01 and PSV359 clinical programs and expanded manufacturing capacity. General and administrative costs eased slightly to $7.0 million from $7.8 million.
Cash, cash equivalents and short-term investments reached $270.9 million, helped by a February 2026 underwritten offering that generated about $175.0 million in gross proceeds. Management believes this cash position can fund planned operations and clinical milestones into late 2027 while it continues to invest in facilities and equipment for future commercial-scale production.
Perspective Therapeutics reported first-quarter 2026 results and highlighted progress across its 212Pb radiopharmaceutical pipeline. Cash, cash equivalents and short-term investments were about $271 million as of March 31, 2026, up from $145 million at year-end 2025, helped by a February underwritten offering that generated roughly $164 million in net proceeds. Management believes this cash should fund current clinical milestones and operations into late 2027.
Research and development expenses rose to $21.4 million from $14.3 million a year earlier as the company expanded staff and clinical and manufacturing activities. General and administrative costs declined to $7.0 million from $7.8 million. Net loss widened to $26.2 million, or $0.25 per share, compared with a loss of $18.2 million, or $0.25 per share, in 2025.
The company reported three clinical-stage programs in neuroendocrine tumors, melanoma and FAP-positive solid tumors, with multiple data and follow-up milestones expected in 2026. It is also expanding a regional manufacturing network, including a flagship Chicago facility planned to complete construction in 2026.
Perspective Therapeutics, Inc. posted an analyst presentation to its website that includes preliminary, estimated financial information and extensive updates on its clinical and manufacturing strategy in targeted oncology. The slides cover its 212Pb-based theranostic programs, including VMT-α-NET for SSTR2+ neuroendocrine tumors and meningioma, along with early data, case studies and treatment landscape context. The presentation also highlights the company’s integrated isotope production, regional manufacturing model and direct-to-hospital delivery aimed at supporting daily production and broad market reach. All financial estimates, including estimated cash, cash equivalents and short-term investments as of March 31, 2026, are unaudited and subject to change after completion of quarter-end procedures.
BlackRock, Inc. reports beneficial ownership of 5,251,363 shares of Perspective Therapeutics Inc. common stock, representing 4.6% of the class as disclosed in this Amendment No. 1 to Schedule 13G/A. The report attributes holdings to certain Reporting Business Units of BlackRock and is signed on 04/27/2026.
Perspective Therapeutics reported updated interim results from its ongoing Phase 1/2a trial of [212Pb]VMT-α-NET in patients with advanced SSTR2-positive neuroendocrine tumors. As of the March 4, 2026 data cut-off, 64 patients had received at least one treatment across three dose cohorts.
The company highlighted a favorable safety profile with no dose-limiting toxicities, no Grade 4 or 5 adverse events, no treatment-related discontinuations, and no serious renal complications or clinically significant treatment-related myelosuppression. Grade 3 or higher treatment-emergent adverse events occurred in 23 patients, and one previously reported Grade 4 lymphopenia was revised to Grade 3.
Among two patients in Cohort 1 and 23 in Cohort 2, 18 of 25 patients (72%) were alive without progression, and 10 of 23 Cohort 2 patients (43%) had objective responses by investigator-assessed RECIST v1.1, with several showing deepening responses over time. Perspective plans further data updates in 2026 and continued regulatory engagement.
Perspective Therapeutics has issued its 2026 proxy for the Annual Meeting to be held on May 27, 2026 at 9:00 a.m. Central Time in Chicago. Stockholders of record as of April 2, 2026, when 114,017,755 common shares were outstanding, may vote.
Investors are asked to elect six directors for one-year terms, ratify WithumSmith+Brown, PC as independent auditor for 2026, and choose how often to hold advisory votes on executive pay. The Board recommends voting “FOR ALL” director nominees, “FOR” auditor ratification, and “1 YEAR” for the say‑on‑frequency proposal.
Perspective Therapeutics filed a Form 8-K to note that it has updated its corporate presentation, which is attached as Exhibit 99.1. The presentation highlights its focus on next-generation radiopharmaceuticals built on a proprietary lead-212 (212Pb) radioligand platform designed to optimize the therapeutic index and targeted tumor delivery.
The company outlines a wholly owned 212Pb-based oncology portfolio, including VMT-α-NET for SSTR2-positive neuroendocrine tumors, VMT01 for melanoma targeting MC1R, and PSV359 targeting FAP-α in solid tumors. Early Phase 1/2a trials are described as showing anti-tumor activity and favorable tolerability, with Phase 1/2 data expected across all three programs in 2026.
Perspective Therapeutics, Inc. describes its business as a clinical-stage radiopharmaceutical company developing precision targeted alpha therapies for cancer. Its platform centers on Lead‑212 (212Pb) therapeutics paired with Lead‑203 (203Pb) imaging to personalize treatment and limit damage to healthy tissue.
The company’s lead programs target neuroendocrine tumors (VMT‑α‑NET), metastatic melanoma (VMT01) and FAP‑α–expressing solid tumors (PSV359), all in Phase 1/2a trials. It highlights Fast Track designations, early clinical signals, and a 2024 option and funding agreement with an affiliate of Lantheus for VMT‑α‑NET and earlier PSMA/GRPR assets.
Perspective is building a distributed manufacturing network using proprietary 212Pb generators, facilities in Iowa and New Jersey, and new sites in Houston, Chicago and Los Angeles. The filing emphasizes substantial ongoing losses, the need for significant additional capital, clinical, regulatory and manufacturing risks, and stock price volatility. As of March 12, 2026, common shares outstanding were 113,933,436.
Perspective Therapeutics reported a larger net loss for 2025 while advancing its radiopharmaceutical pipeline and strengthening its balance sheet. Net loss was $103.1 million, or $1.40 per share, compared with $79.3 million, or $1.23 per share in 2024, driven mainly by higher research and development spending.
Research and development expenses rose to $84.2 million, up about 102%, as the company expanded clinical activities for its VMT-α-NET, VMT01 and PSV359 programs and recorded a $10.0 million non-cash impairment on a deprioritized preclinical asset. General and administrative expenses increased to $30.2 million from $26.6 million.
Cash, cash equivalents and short-term investments were about $145 million as of December 31, 2025, down from $227 million a year earlier. In February 2026, the company closed an underwritten equity offering with net proceeds of approximately $164 million, and now expects its cash resources to fund planned clinical milestones and operations into late 2027.